Literature DB >> 28094348

Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.

G N Almeida-Paulo1, I Dapía García2, R Lubomirov1, A M Borobia1, N L Alonso-Sánchez1, L Espinosa3, A J Carcas-Sansuán1.   

Abstract

Tacrolimus (TAC) is highly effective for the prevention of acute organ rejection. However, its clinical use may be challenging due to its large interindividual pharmacokinetic variability, which can be partially explained by genetic variations in TAC-metabolizing enzymes and transporters. The aim of this study was to evaluate the influence of genetic and clinical factors on TAC pharmacokinetic variability in 21 stable pediatric renal transplant patients. This study was nested in a previous Prograf to Advagraf conversion clinical trial. CYP3A5, ABCB1 and two POR genotypes were assessed by real-time PCR. The impact on TAC pharmacokinetics of individual genetic variants on CYP3A5 nonexpressors was evaluated by genetic score. Explicative models for TAC AUC0-24h, Cmax and Cmin after Advagraf were developed by linear regression. The built genetic scores explain 13.7 and 26.5% of the total AUC0-24h and Cmin total variability, respectively. Patients genetic information should be considered to monitorizate and predict TAC exposure.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28094348     DOI： 10.1038/tpj.2016.93

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


  45 in total

Review 1.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

Authors:  Anna L Taylor; Christopher J E Watson; J Andrew Bradley
Journal:  Crit Rev Oncol Hematol       Date:  2005-10       Impact factor: 6.312

Review 2.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

3.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.

Authors:  R P Kershner; W E Fitzsimmons
Journal:  Transplantation       Date:  1996-10-15       Impact factor: 4.939

4.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.

Authors:  D A Laskow; F Vincenti; J F Neylan; R Mendez; A J Matas
Journal:  Transplantation       Date:  1996-10-15       Impact factor: 4.939

5.  Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Authors:  X-J Shi; F Geng; Z Jiao; X-Y Cui; X-Y Qiu; M-K Zhong
Journal:  J Clin Pharm Ther       Date:  2010-10-05       Impact factor: 2.512

6.  The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function.

Authors:  Michel Mourad; Pierre Wallemacq; Martine De Meyer; Dimitri Brandt; Valérie Van Kerkhove; Jacques Malaise; Djamila Chaïb Eddour; Dominique Lison; Vincent Haufroid
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

7.  Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Norihiko Tsuchiya; Shigeru Satoh; Hitoshi Tada; Zhenhua Li; Chikara Ohyama; Kazunari Sato; Toshio Suzuki; Tomonori Habuchi; Tetsuro Kato
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

8.  Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Authors:  Eric Thervet; Dany Anglicheau; Barry King; Marie-Hélène Schlageter; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Ann K Daly
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

9.  The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring.

Authors:  Claudia R Felipe; Helio T Silva; Paula G P Machado; Riberto Garcia; Silvia R da Silva Moreira; José O M Pestana
Journal:  Clin Transplant       Date:  2002-08       Impact factor: 2.863

10.  Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.

Authors:  Xiaobo Yu; Haiyang Xie; Bajin Wei; Min Zhang; Weilin Wang; Jian Wu; Sheng Yan; Shusen Zheng; Lin Zhou
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240
View more
  4 in total

Review 1.  Genetics of acute rejection after kidney transplantation.

Authors:  Casey R Dorr; William S Oetting; Pamala A Jacobson; Ajay K Israni
Journal:  Transpl Int       Date:  2017-11-08       Impact factor: 3.782

2.  Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis.

Authors:  Lizhi Chen; Yunyun Yang; Xuebin Wang; Chenyu Wang; Weiwei Lin; Zheng Jiao; Zhuo Wang
Journal:  Pharmgenomics Pers Med       Date:  2021-09-03

3.  A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients.

Authors:  Yuan Liu; Tao Zhang; Xiaoqing Zhang; Ling Ye; Haitao Gu; Lin Zhong; Hongcheng Sun; Chenlong Song; Zhihai Peng; Junwei Fan
Journal:  Oncotarget       Date:  2017-07-26

4.  Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation.

Authors:  Takahiro Nakamura; Mio Fukuda; Ryosuke Matsukane; Kimitaka Suetsugu; Noboru Harada; Tomoharu Yoshizumi; Nobuaki Egashira; Masaki Mori; Satohiro Masuda
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.